| Autor: |
Baur M; Ludwig Boltzmann Institute for Applied Cancer Research (LBI-ACR VIEnna), 3rd Medical Department of Oncology, Kaiser Franz Josef-Spital, Kundratstrasse 3, 1100-Vienna, Austria., Walter R, Gebauer A, Tscholakoff D, Lochs H, Mühlbacher F, Turetschek K, Binder R, Hudec M, Gangl A, Ferenci P, Dittrich C |
| Jazyk: |
angličtina |
| Zdroj: |
International journal of oncology [Int J Oncol] 2003 Sep; Vol. 23 (3), pp. 811-9. |
| Abstrakt: |
Arterial chemoembolization with subsequent systemic chemotherapy was assessed prospectively. Of 94 consecutive patients with HCC, 31 patients were considered to have inoperable disease and were selected for chemoembolization. Twenty-two of the 31 patients underwent chemoembolization. In eight patients, technical problems with catheterization prevented the application of therapy, and one patient rejected further treatment. Regimen: Three monthly cycles of chemoembolization with cisplatin 20 mg/m(2) mixed with lipiodol delivered intraarterially with Gelfoam or collagen on day 1, followed by intravenous chemotherapy with cisplatin 60 mg/m(2) on day 2; interferon alpha-2c 30 microg (10 M IU) subcutaneously on days 2, 5, 9, and 12. Three percent of the patients (1/31) (CI 95% 0.08; 16.7) experienced a partial clinical response, in 53% alpha-fetoprotein levels decreased by more than 50%. On univariate analysis, performance status, Child score, Okuda stage, albumin levels, and lactate dehydrogenase were found to have an effect on survival. Postchemoembolization syndrome occurred in 68% of the patients, nausea/vomiting grades 3/4 (according to the World Health Organization WHO) in six patients, anemia grade 3 in three patients, leukopenia grade 3 in one patient and thrombocytopenia grade 3 in one patient. This treatment regimen is a very selective procedure. Because of the low response rate it is not recommended for routine clinical use. |
| Databáze: |
MEDLINE |
| Externí odkaz: |
|
